Medicines and Healthcare products Regulatory Agency CERTIFICATE NUMBER : UK API 8931 Insp GMP 8931/646098-0008 [H] CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER(1),(2)

Part 1

Issued following an inspection in accordance with : Regulation 331A of The Human Medicines Regulations 2012 (SI 2012/1916)

The competent authority of United Kingdom confirms the following :

The Manufacturer : DR REDDY'S LABORATORIES (EU) LIMITED

Site address : DR REDDY'S LABORATORIES (EU) LIMITED, STEANARD LANE, MIRFIELD, WF14 8HZ, UNITED KINGDOM

Is an active substance manufacturer that has been inspected in accordance with Regulation 327 of The Human Medicines Regulations 2012 (SI 2012/1916).

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 07/02/2025, it is considered that it complies with

• The principles of GMP for active substances referred to in Regulation B17 and C17 of the Human Medicines Regulations 2012 (SI 2012/1916)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in MHRA-GMDP. If it does not appear, please contact the issuing authority.

- (1) Guidance on the interpretation of this template can be found in the Help menu of MHRA-GMDP database.
- (2) These requirements fulfil the GMP recommendations of WHO.

Part 2

Human Medicinal Products

Manufacture of active substance. Names of substances subject to inspection :

- [1000012358] LUBIPROSTONE
- [1000010532] TREPROSTINIL
- [2000017046] PERMETHRIN MEDICAL GRADE VETERINARY CIS:TRANS 40:60
- [1000020359] DELGOCITINIB
- [100000660] TRAVOPROST
- [4000007597] PERMETHRIN MEDICAL GRADE CIS/TRANS ISOMERS 25/75

3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

LUBIPROSTONE		
3.1	Manufacture of Active Substance by Chemical Synthesis	
	3.1.1 Manufacture Of Active Substance Intermediates	
	3.1.2 Manufacture Of Crude Active Substance	
	3.1.3 Salt Formation/Purification steps (eg. Crystallisation) crystallisation	
3.5	General Finishing Steps	
	3.5.1 Physical Processing Steps	
	drying	
	3.5.2 Primary Packaging	~
	3.5.3 Secondary Packaging	0
3.6	Quality Control Testing	
0.0	3.6.1 Physical / Chemical testing	
NYV	S.C.T Thysical / Onemical testing	NY V
TREPROSTINIL		
3.1	Manufacture of Active Substance by Chemical Synthesis	
	3.1.1 Manufacture Of Active Substance Intermediates	
	3.1.2 Manufacture Of Crude Active Substance	
	3.1.3 Salt Formation/Purification steps (eg. Crystallisation) chromatography, crystallisation	
3.5	General Finishing Steps	
	3.5.1 Physical Processing Steps	
	drying	
	3.5.2 Primary Packaging	
	3.5.3 Secondary Packaging	
3.6	Quality Control Testing	
	3.6.1 Physical / Chemical testing	
	3.6.2 Microbiological testing (excluding sterility testing)	2
	DE VETERINARY CIS:TRANS 40:60	
3.1	Manufacture of Active Substance by Chemical Synthesis	
	3.1.1 Manufacture Of Active Substance Intermediates	NYV
V_{II}	3.1.2 Manufacture Of Crude Active Substance	

3.5	General Finishing Steps
	3.5.2 Primary Packaging
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
DELGOCITINIB	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture Of Active Substance Intermediates
	3.1.2 Manufacture Of Crude Active Substance
	3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Crystallisation
3.5	General Finishing Steps
5.5	3.5.1 Physical Processing Steps
	drying
	3.5.2 Primary Packaging
1.	3.5.3 Secondary Packaging
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
TRAVOPROST	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture Of Active Substance Intermediates
	3.1.2 Manufacture Of Crude Active Substance
	3.1.3 Salt Formation/Purification steps (eg. Crystallisation)
	chromatography, crystallisation
3.5	General Finishing Steps
	3.5.1 Physical Processing Steps desolvation (the API is a liquid)
	3.5.2. Primary Packaging
	3.5.3 Secondary Packaging
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
	DE CIS/TRANS ISOMERS 25/75
3.1	Manufacture of Active Substance by Chemical Synthesis

	3.1.1 Manufacture Of Active Substance Intermediates
	3.1.2 Manufacture Of Crude Active Substance
	3.1.3 Salt Formation/Purification steps (eg. Crystallisation) crystallisation
3.5	General Finishing Steps
	3.5.1 Physical Processing Steps
	desolvation (the API is a liquid)
	3.5.2 Primary Packaging
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
18/06/2025 Name and sig	gnature of the authorised person of the Competent Authority of United Kingdom
Confidential	
	d Healthcare products Regulatory Agency
Tel : Confider	htiai
N.	
Certificate Number: UK API 893	1 Insp GMP 8931/646098-

Certificate Number: UK API 8931 Insp	o GMP 8931/646098-
0008 [H]	